Validation of a next-generation sequencing oncology panel optimized for low input DNA.
Sussman RT*, Shaffer S*, Azzato EM*, DeSloover D, Farooqi MS, Meyer A, Lieberman DB, Bigdeli A, Paolillo C, Ganapathy K, Sukhadia S, Rosenbaum JN, Daber RD, Morrissette JJD. *equal contributions
Cancer Genetics. 2018 December. journal website
Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance.
Shaffer SM, Dunagin MC, Torborg SR, Torre EA, Emert B, Krepler C, Beqiri M, Sproesser K, Brafford PA, Xiao M, Eggan E, Anastopoulos IN, Vargas-Garcia CA, Singh A, Nathanson KL, Herlyn M, Raj A.